biostudies-literatureUnknown16(1)Wei CYIncorporating pharmacogenetics into clinical practice promises to improve therapeutic outcomes by optimizing drug selection and dosage based on genetic factors affecting drug response. A key advantage of PGx-guided therapy is to decrease the likelihood of adverse events. To evaluate the clinical impact of PGx risk variants, we performed a retrospective study using genetic and clinical data from the largest Han Chinese cohort, comprising 486,956 individuals, assembled by the Taiwan Precision Medicine Initiative. We found that nearly all participants carried at least one genetic variant that could affect drug response, with many carrying multiple risk variants. Here we show the detailed analyses of four gene-drug pairs, azathioprine (NUDT15/TPMT), clopidogrel (CYP2C19), statins (ABCG2/CYP2C9Nature communications6344https://www.ebi.ac.uk/biostudies/studies/S-EPMC12241563biostudies-literatureClinical impact of pharmacogenetic risk variants in a large chinese cohort.PMC12241563Chang TCChen PYChiang HSTarng DCLi PFHong TCChen HHChang CHKwok PYLiu YMChang CCChiu MCSu CWHu CJChen HCChang SJYeh ECTsai MFWu DCChang SMSin JChu PLu CLChan LHwang JJWang YFLin TKTsai MTChang JHKan JYLin LYTung HYang SFTsui KYen TTLee CWKuo HCWei CYWu JYKao HLYang HCPeng YCChien CCLan KHLai JHCheng HTLee SLHsieh YCTsai CTSu SCChang TYTsai CLLiu YTTsai CKFann CSLing SZWang SJChang LCFuh JLLiou MSWang SPLi LHYao TCMao CLHuang CCLin YWHuang CFLin YKLi CPWu YFChiu YLSheu CCLuo SFLi CCKuo CFMa GCCheng CKKao KJChan TMLai CHChen CDChen SSChen CHChen KMWen MSJeng JSChen SPLin YFYen HCHuang CYHung CFChen SCLu HJHsiao THYu JJChuang HPHsu CYLee YCLin KTHuang YHYang LJLin CMLiao YJHsiao SMHsiao BYLin CHHuang YTLin JCTang SEChang YLLee WJHuo TIChen YTChen ICChen YJSheen YJChen YMfalseClinical impact of pharmacogenetic risk variants in a large chinese cohort.Incorporating pharmacogenetics into clinical practice promises to improve therapeutic outcomes by optimizing drug selection and dosage based on genetic factors affecting drug response. A key advantage of PGx-guided therapy is to decrease the likelihood of adverse events. To evaluate the clinical impact of PGx risk variants, we performed a retrospective study using genetic and clinical data from the largest Han Chinese cohort, comprising 486,956 individuals, assembled by the Taiwan Precision Medicine Initiative. We found that nearly all participants carried at least one genetic variant that could affect drug response, with many carrying multiple risk variants. Here we show the detailed analyses of four gene-drug pairs, azathioprine (NUDT15/TPMT), clopidogrel (CYP2C19), statins (ABCG2/CYP2C92025-01-01T00:00:00Z2025 Jul2026-06-06T13:46:46.629Z2026-05-31T03:10:18.976ZS-EPMC122415634063430010.1038/s41467-025-61644-x